

# Anna S Schwendeman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6235186/publications.pdf>

Version: 2024-02-01

83  
papers

4,514  
citations

147801

31  
h-index

110387

64  
g-index

85  
all docs

85  
docs citations

85  
times ranked

5723  
citing authors

#	ARTICLE	IF	CITATIONS
1	Kräppel-like factor 14 deletion in myeloid cells accelerates atherosclerotic lesion development. <i>Cardiovascular Research</i> , 2022, 118, 475-488.	3.8	15
2	Replenishing HDL with synthetic HDL has multiple protective effects against sepsis in mice. <i>Science Signaling</i> , 2022, 15, eabl9322.	3.6	14
3	Streamlining the Characterization of Disulfide Bond Shuffling and Protein Degradation in IgG1 Biopharmaceuticals Under Native and Stressed Conditions. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 862456.	4.1	8
4	Systemic Delivery of an Adjuvant CXCR4/CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. <i>ACS Nano</i> , 2022, 16, 8729-8750.	14.6	43
5	Synthetic high-density lipoprotein nanoparticles delivering rapamycin for the treatment of age-related macular degeneration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 44, 102571.	3.3	5
6	Nanodisc delivery of liver X receptor agonist for the treatment of diabetic nephropathy. <i>Journal of Controlled Release</i> , 2022, 348, 1016-1027.	9.9	8
7	Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport. <i>Journal of Controlled Release</i> , 2021, 329, 361-371.	9.9	25
8	Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 158, 401-409.	4.3	21
9	Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	70
10	Overview of Humira® Biosimilars: Current European Landscape and Future Implications. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1572-1582.	3.3	22
11	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. <i>Frontiers in Pharmacology</i> , 2021, 12, 680021.	3.5	33
12	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 631037.	2.8	10
13	Artificial high-density lipoprotein-mimicking nanotherapeutics for the treatment of cardiovascular diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1737.	6.1	11
14	The Effects of pH and Excipients on Exenatide Stability in Solution. <i>Pharmaceutics</i> , 2021, 13, 1263.	4.5	10
15	Vaccine nanodiscs plus poly(I)C/LC elicit robust CD8+ T cell responses in mice and non-human primates. <i>Journal of Controlled Release</i> , 2021, 337, 168-178.	9.9	16
16	Collision-Induced Unfolding Reveals Stability Differences in Infliximab Therapeutics under Native and Heat Stress Conditions. <i>Analytical Chemistry</i> , 2021, 93, 16166-16174.	6.5	10
17	Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. <i>EBioMedicine</i> , 2021, 74, 103725.	6.1	16
18	High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. <i>Arthritis and Rheumatology</i> , 2020, 72, 20-30.	5.6	51

#	ARTICLE	IF	CITATIONS
19	Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 763-775.	3.7	19
20	Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 146, 111-124.	4.3	21
21	Hybrid Antimicrobial Hydrogel as Injectable Therapeutics for Oral Infection Ablation. <i>Biomacromolecules</i> , 2020, 21, 3945-3956.	5.4	49
22	Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs. <i>Nano Letters</i> , 2020, 20, 7783-7792.	9.1	55
23	Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice. <i>Science Advances</i> , 2020, 6, .	10.3	11
24	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 659-684.	4.1	15
25	Robust Anti-tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy. <i>Advanced Therapeutics</i> , 2020, 3, 2000094.	3.2	11
26	Injectable MMP-Responsive Nanotube-Modified Gelatin Hydrogel for Dental Infection Ablation. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 16006-16017.	8.0	69
27	Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1777.	4.1	26
28	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1234-1236.	5.6	0
29	Microencapsulation of luteinizing hormone-releasing hormone agonist in poly (lactic-co-glycolic) Tj ETQq1 1 0.784314 rgBT /Overlock	9.9	48
30	Structural analysis of lecithin:cholesterol acyltransferase bound to high density lipoprotein particles. <i>Communications Biology</i> , 2020, 3, 28.	4.4	30
31	Prospects of biological and synthetic pharmacotherapies for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 305-317.	3.1	16
32	Electrospinning of dexamethasone/cyclodextrin inclusion complex polymer fibers for dental pulp therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 191, 111011.	5.0	42
33	Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 372, 193-204.	2.5	17
34	High-density lipoproteins during sepsis: from bench to bedside. <i>Critical Care</i> , 2020, 24, 134.	5.8	110
35	Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas. <i>Clinical Cancer Research</i> , 2020, 26, 4369-4380.	7.0	48
36	Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 513031.	3.5	10

#	ARTICLE	IF	CITATIONS
37	Analytical method development and comparability study for AmBisome® and generic Amphotericin B liposomal products. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 157, 241-249.	4.3	10
38	Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer. <i>Surgery</i> , 2019, 166, 1168-1175.	1.9	10
39	Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures. <i>Accounts of Chemical Research</i> , 2019, 52, 2445-2461.	15.6	333
40	Engineering patient-specific cancer immunotherapies. <i>Nature Biomedical Engineering</i> , 2019, 3, 768-782.	22.5	123
41	Predicting drug release kinetics from nanocarriers inside dialysis bags. <i>Journal of Controlled Release</i> , 2019, 315, 23-30.	9.9	94
42	Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases. <i>BMC Medicine</i> , 2019, 17, 200.	5.5	19
43	High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. <i>ACS Nano</i> , 2019, 13, 1365-1384.	14.6	122
44	Inkjet-printed micro-calibration standards for ultraquantitative Raman spectral cytometry. <i>Analyst</i> , 2019, 144, 3790-3799.	3.5	5
45	&lt;p&gt;Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 3069-3086.	6.7	21
46	Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 134, 107-116.	4.3	30
47	Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2018, 29, 771-775.	3.6	68
48	Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. <i>Science Advances</i> , 2018, 4, eaao1736.	10.3	269
49	High-density lipoprotein-mimicking nanodiscs carrying peptide for enhanced therapeutic angiogenesis in diabetic hindlimb ischemia. <i>Biomaterials</i> , 2018, 161, 69-80.	11.4	29
50	Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression. <i>EBioMedicine</i> , 2018, 28, 225-233.	6.1	74
51	Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. <i>Journal of Controlled Release</i> , 2018, 282, 131-139.	9.9	104
52	Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics. <i>Molecular Pharmaceutics</i> , 2018, 15, 83-96.	4.6	18
53	HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. <i>Frontiers in Endocrinology</i> , 2018, 9, 715.	3.5	24
54	Reverse Engineering the 1-Month Lupron Depot®. <i>AAPS Journal</i> , 2018, 20, 105.	4.4	37

#	ARTICLE	IF	CITATIONS
55	Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal. <i>Surgery</i> , 2018, 164, 165-172.	1.9	8
56	NanoDDS 2017: The 15th International Nanomedicine & Drug Delivery Symposium. <i>Journal of Controlled Release</i> , 2018, 282, 1-2.	9.9	0
57	Battle of GLP-1 delivery technologies. <i>Advanced Drug Delivery Reviews</i> , 2018, 130, 113-130.	13.7	84
58	Guest Editorial Title: Nanomedicine: past, present, and future. <i>Advanced Drug Delivery Reviews</i> , 2018, 130, 1-2.	13.7	1
59	Infliximab Biosimilars in the Age of Personalized Medicine. <i>Trends in Biotechnology</i> , 2018, 36, 987-992.	9.3	12
60	Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol. <i>ELife</i> , 2018, 7, .	6.0	37
61	Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 602-611.	0.9	44
62	Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1869-1878.	3.3	45
63	A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. <i>Analytical Chemistry</i> , 2017, 89, 4838-4846.	6.5	64
64	Designer vaccine nanodiscs for personalized cancer immunotherapy. <i>Nature Materials</i> , 2017, 16, 489-496.	27.5	817
65	A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I. <i>Journal of Biological Chemistry</i> , 2017, 292, 20313-20327.	3.4	32
66	Printing of small molecular medicines from the vapor phase. <i>Nature Communications</i> , 2017, 8, 711.	12.8	12
67	Biosimilarity under stress: A forced degradation study of Remicade <sup>®</sup> and Remsima <sup>®</sup> . <i>MAbs</i> , 2017, 9, 1197-1209.	5.2	36
68	Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes. <i>AAPS Journal</i> , 2017, 19, 150-160.	4.4	30
69	Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization. <i>Journal of Lipid Research</i> , 2017, 58, 124-136.	4.2	24
70	Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6581-6594.	6.7	29
71	Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 6229-6238.	6.7	34
72	Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVVC development I: In vitro evaluation. <i>Journal of Controlled Release</i> , 2016, 244, 302-313.	9.9	60

#	ARTICLE	IF	CITATIONS
73	Validation of a cage implant system for assessing in vivo performance of long-acting release microspheres. <i>Biomaterials</i> , 2016, 109, 88-96.	11.4	23
74	Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells. <i>Endocrinology</i> , 2016, 157, 3122-3129.	2.8	5
75	Reconstitution of the Cyt <i>b</i> <sub>5</sub> -CytP450 Complex in Nanodiscs for Structural Studies using NMR Spectroscopy. <i>Angewandte Chemie</i> , 2016, 128, 4573-4575.	2.0	13
76	Reconstitution of the Cyt <i>b</i> <sub>5</sub> -CytP450 Complex in Nanodiscs for Structural Studies using NMR Spectroscopy. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 4497-4499.	13.8	80
77	High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. <i>ACS Nano</i> , 2016, 10, 3015-3041.	14.6	255
78	Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas. <i>Surgery</i> , 2016, 159, 284-295.	1.9	29
79	HDL in sepsis – risk factor and therapeutic approach. <i>Frontiers in Pharmacology</i> , 2015, 6, 244.	3.5	90
80	The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties. <i>Journal of Lipid Research</i> , 2015, 56, 1727-1737.	4.2	93
81	Apolipoprotein Mimetic Peptides for Stimulating Cholesterol Efflux. , 2015, , 29-42.		22
82	Injectable controlled release depots for large molecules. <i>Journal of Controlled Release</i> , 2014, 190, 240-253.	9.9	157
83	Abstract 448: The Association of 5A Peptide With Sphingomyelin Increases Its Ability to Efflux Cholesterol Both in vitro and in vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	2.4	0